1.Signals mining and analysis of inebilizumab adverse events
Jiayi ZHANG ; Chen LIU ; Xiaotong ZHANG
China Pharmacy 2026;37(2):215-219
OBJECTIVE To mine and analyze adverse event signals associated with inebilizumab, and to provide reference for safe and rational clinical use. METHODS Reports of adverse event related to inebilizumab were collected from the FDA adverse event reporting system (FAERS) database, from Q2 2020 to Q4 2024. Adverse events were standardized and categorized according to the preferred term (PT) and system organ class (SOC) of the Medical Dictionary for Regulatory Activities (MedDRA) version 26.0. Signals were mined using the reporting odds ratio (ROR) method and the Bayesian confidence propagation neural network (BCPNN) method. RESULTS A total of 783 adverse event reports with inebilizumab as the primary suspected drug were identified, involving 297 patients. Most reports originated from the United States and Japan, with physicians being the primary reporters. Female patients outnumbered males, and the most common age group was 45-64 years. Using the ROR method and BCPNN method, a total of 29 valid adverse event signals were detected, involving 12 SOCs and comprising 225 adverse event reports. The five most frequently reported PTs were headache, nausea, fatigue, infectious pneumonia and arthralgia. The five PTs with the strongest signal intensity were: B-cell recovery, decreased blood immunoglobulin G, spinal compression fracture, COVID-19 and acute respiratory distress syndrome. Among the 29 valid signals for adverse event, 19 were not documented in the drug package inserts, involving 10 SOCs and comprising 107 adverse event reports. These encompassed nervous system disorders, general disorders and administration site conditions, eye disorders, among others. CONCLUSIONS Inebilizumab treatment not only causes adverse events documented in the product information, such as infections, immunoglobulin reduction and infusion-related reactions but also leads to potential signals, including B-cell recovery, spinal compression fracture. When using this drug in clinical practice, the patient’s risk of infection and baseline immune status should be assessed, relevant indicators should be closely monitored, and targeted preventive measures should be considered when necessary.
2.Repair strategies for nonunion in old osteoporotic vertebral compression fractures:a case analysis
Xingcheng ZHAO ; Jun WANG ; Ming LU
Chinese Journal of Tissue Engineering Research 2025;29(3):538-546
BACKGROUND:Patients with osteoporotic compression fractures of the lumbar spine have varying degrees of changes in the sagittal parameters of the spine and pelvis,resulting in disequilibrium and rebalancing of the sagittal plane of the whole spine/lumbar spine.If the primary osteoporotic vertebral compression fracture is not treated promptly,it develops into an old osteoporotic vertebral compression fracture with nonunion over time. OBJECTIVE:To observe the effect of percutaneous vertebroplasty in nine patients with old osteoporotic lumbar compression fracture with nonunion. METHODS:A retrospective analysis was conducted on the clinical data of nine elderly patients with old osteoporotic lumbar compression fractures with nonunion treated in the Orthopedics Department of Shanghai Public Health Clinical Center from September 2018 to August 2022.All patients underwent revision treatment with percutaneous vertebroplasty and received regular anti-osteoporosis treatment and rehabilitation training.The lumbar spine X-ray plain film and three-dimensional CT test results were reviewed before discharge and during follow-up to evaluate the diffusion of bone cement.Visual analog scale score,lumbar Oswestry disability index score,and Roussouly classification were recorded before,after surgery and during follow-up. RESULTS AND CONCLUSION:(1)During postoperative follow-up,none of the 9 cases in this group experienced serious surgical complications such as nerve injury,infection,bone cement leakage,pulmonary embolism,and allergic shock,and no adverse reactions related to bone cement occurred.One patient died of respiratory failure due to COVID-19 infection 2 years after operation.(2)The visual analog scale score and Oswestry disability index score of postoperative pain in patients with recurrent vertebral fractures after percutaneous vertebroplasty were significantly lower than those before revision surgery.After the last follow-up percutaneous vertebroplasty revision surgery,the Roussouly classification of patients significantly improved.There was no statistically significant difference between the changes in vertebral body height during the last follow-up measurement and preoperative comparison.(3)These findings indicate that for patients with old osteoporotic lumbar compression fractures with nonunion,moderate injection of bone cement and effective dispersion of bone cement have a significant relieving effect on postoperative pain.Regular anti-osteoporosis and effective postoperative rehabilitation training can help patients improve their postoperative lumbar spine function.
3.Characteristics of public health emergencies in Jinhua City from 2014 to 2023
ZHANG Tao ; DU Zhiping ; WANG Zuoyi ; JIN Lü ; hua
Journal of Preventive Medicine 2025;37(1):69-72
Objective:
To investigate the characteristics of public health emergencies in Jinhua City, Zhejiang Province from 2014 to 2023, so as to provide the reference for prevention and control of public health emergencies.
Methods:
Data of public health emergencies and related information in Jinhua City from 2014 to 2023 were collected through Emergency Public Reporting System of Chinese Disease Prevention and Control Information System. Attack rates, and distribution of time, areas and places were descriptively analyzed.
Results:
A total of 276 public health emergencies were reported in Jinhua City from 2014 to 2023. There were 10 324 reported cases and 7 deaths, with an attack rate of 0.32%. There were 53 Ⅳ-level (19.20%) and 223 unclassified public health emergencies (80.80%). Infectious disease emergencies were predominant types, accounting for 97.83% (270 events). The three most common infectious disease emergencies were other infectious diarrhea (42.03%), influenza (21.01%) and COVID-19 (16.30%). The reported public health emergencies peaked in November and December, with 66 and 45 events reported, respectively. The three most counties (cities, districts) included Yiwu City, Wucheng District and Lanxi City, accounting for 24.28% (67 events), 18.48% (51 events) and 11.96% (33 events), respectively. School and preschool institutions were predominant places where public health emergencies occurred (198 events, 71.74%).
Conclusions
The public health emergencies in Jinhua City from 2014 to 2023 were Ⅳ-level and unclassified emergencies, and infectious disease emergencies were predominant. November and December were the peak reporting periods, and schools and preschool institutions were the main places where these events occurred.
4.Current developments in dry eye induced by video display terminals-derived blue light
Yingying SUN ; Jianxiong PENG ; Min LU
International Eye Science 2025;25(2):255-258
With the development of science and technology, electronic devices have become an inevitable part of our daily life and work. There has been an increase of interest in the use of various video display terminals(VDT). The ocular surface is the first barrier of the visual system to resist the damage of the external environment. In recent years, the number of patients with dry eye has consistently increased with the excessive use of VDT. Blue light produced by VDT, with wavelengths ranging from 400 to 500 nm, has a high energy in visible light. Therefore, blue light may also be an important risk factor for dry eye. In particular, the outbreak of COVID-19 has left people worldwide suffering from increased blue light, which promotes further research into dry eye caused by blue light emitted from VDT. In this review, we summarize the recent studies on the role of blue light produced by VDT in dry eye to provide reference for future related research.
5.ICU-acquired muscle weakness in COVID-19 patients who underwent lung transplantation
World Journal of Emergency Medicine 2025;16(1):94-96
Lung transplantation (LT) has emerged as a crucial life-saving option for critically ill patients with severe coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS) or irreversible lung injury.[1] Intensive care unit-acquired weakness (ICU-AW) is a prevalent complication in critically ill patients.[2] The recovery of recipients undergoing LT for COVID-19-related respiratory failure may face impediments due to ICU-AW, which negatively affects early mobilization and functional improvement. This study describes two cases of successful bilateral LT for severe COVID-19-related ARDS with the occurrence of ICU-AW and subsequent successful discharge.
6.Chinese expert consensus on the evaluation and postoperative management of lung transplant recipient in COVID-19 patients
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery 2025;32(01):1-7
Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic at the end of December 2019, more than 85% of the population in China has been infected. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mainly affects the respiratory system, especially the lungs. The mortality rate of patients with severe infection is high. A percentage of 6% to 10% of patients will eventually develop into COVID-related acute respiratory distress syndrome (CARDS), which requires mechanical ventilation and extracorporeal membrane oxygenation (ECMO) support. Some patients who survive acute lung injury will subsequently develop post COVID-19 pulmonary fibrosis (PCPF). Both fully treated CARDS and severe PCPF are suitable candidates for lung transplantation. Due to the special course, evaluation strategies are different from those used in patients with common end-stage lung disease. After lung transplantation in COVID-19 patients, special treatment is required, including standardized nucleic acid testing for the novel coronavirus, adjustment strategy of immunosuppressive drugs, and rational use of antiviral drugs, which is a big challenge for the postoperative management of lung transplantation. This consensus was evidence-based written and was reached by experts after multiple rounds of discussions, providing reference for assessment and postoperative management of patients with interstitial pneumonia after COVID-19 infection.
7.Experience of Using Shengyang Yiwei Decoction (升阳益胃汤) in the Treatment of Pediatric Diseases
Yumeng YANG ; Caiping CUI ; Xiaoya CHEN ; Jianmin WANG
Journal of Traditional Chinese Medicine 2025;66(3):304-307
It is believed that Shengyang Yiwei Decoction (升阳益胃汤, SYD) is effective in regulating the flow of Qi (气), and can treat various diseases caused by the disorder of the spleen and stomach Qi. In clinical practice, based on the pathological characteristics of children often having insufficient spleen, and adhering to the principle of treating different diseases with the same method, the focus is placed on the core pathogenesis of spleen and stomach Qi disharmony. We use SYD in various pediatric conditions such as allergic rhinitis, post COVID-19 condition, urethral syndrome, and dysfunctional uterine bleeding in adolescence, and emphasize the treatment is flexibly tailored to the symptoms.
8.The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”
Donghee KIM ; Pojsakorn DANPANICHKUL ; Karn WIJARNPREECHA ; George CHOLANKERIL ; Rohit LOOMBA ; Aijaz AHMED
Clinical and Molecular Hepatology 2025;31(2):e183-e185
10.Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023
Donghee KIM ; Pojsakorn DANPANICHKUL ; Karn WIJARNPREECHA ; George CHOLANKERIL ; Rohit LOOMBA ; Aijaz AHMED
Clinical and Molecular Hepatology 2025;31(2):382-393
Background/Aims:
Multi-society experts proposed the adoption of new terminology, metabolic dysfunctionassociated steatotic liver disease (MASLD) and steatotic liver disease (SLD). We studied the current prevalence of SLD and its subcategories in the US.
Methods:
Using the recent National Health and Nutrition Examination Survey from 2017 to 2023, we analyzed data from 12,199 participants (≥18 years) who completed transient elastography. SLD and its subcategories, including MASLD, metabolic and alcohol-related liver disease (MetALD), and alcohol-related liver disease (ALD), were categorized according to consensus nomenclature.
Results:
The age-adjusted prevalence of SLD (cut-off: 285 dB/m) was 35.0% (95% confidence interval [CI] 33.4–36.7). Within this category, the age-adjusted prevalence for MASLD was 31.9% (95% CI 30.4–33.4), MetALD 2.2% (95% CI 1.8–2.6), and ALD 0.8% (95% CI 0.6–1.1). The prevalence of SLD and MASLD showed a statistically insignificant decrease during COVID-19, while ALD increased without significance. In contrast, the prevalence of advanced fibrosis in SLD was significantly higher during the COVID-19 era, at 9.8% for 285 dB/m and 7.8% for 263 dB/m, compared to 7.4% (P=0.039) and 6% (P=0.041) in the pre-COVID-19 era. The proportion of advanced fibrosis and cirrhosis in individuals with ALD was two-fold higher than MASLD and MetALD, largely due to increases during the COVID-19 era.
Conclusions
While the prevalence of SLD and its subcategories remained stable, there was a significant increase in advanced fibrosis among SLD individuals during the COVID-19 era, with ALD having a proportion of advanced fibrosis and cirrhosis that was twice as high as MASLD and MetALD.


Result Analysis
Print
Save
E-mail